Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Average Rating of “Moderate Buy” from Analysts

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has earned an average recommendation of “Moderate Buy” from the seven research firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $17.1667.

KPTI has been the subject of a number of research analyst reports. HC Wainwright upped their price target on Karyopharm Therapeutics from $8.00 to $13.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Piper Sandler reiterated an “overweight” rating and set a $16.00 price target (up from $8.00) on shares of Karyopharm Therapeutics in a report on Monday, April 27th. Robert W. Baird cut their price target on Karyopharm Therapeutics from $21.00 to $15.00 and set an “outperform” rating for the company in a report on Wednesday, March 25th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Karyopharm Therapeutics in a report on Tuesday, June 9th. Finally, Rodman & Renshaw upgraded Karyopharm Therapeutics to a “strong-buy” rating in a report on Tuesday, March 10th.

Karyopharm Therapeutics Stock Down 5.6%

Shares of Karyopharm Therapeutics stock opened at $9.10 on Wednesday. The stock has a market capitalization of $206.23 million, a P/E ratio of -0.60 and a beta of 0.83. The stock has a 50 day moving average price of $8.61 and a two-hundred day moving average price of $7.74. Karyopharm Therapeutics has a 12-month low of $3.65 and a 12-month high of $10.99.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its earnings results on Thursday, May 14th. The company reported ($1.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.45) by $0.21. The company had revenue of $35.07 million for the quarter, compared to the consensus estimate of $31.40 million. Sell-side analysts anticipate that Karyopharm Therapeutics will post -3.24 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of KPTI. Avidity Partners Management LP raised its stake in shares of Karyopharm Therapeutics by 244.6% in the first quarter. Avidity Partners Management LP now owns 463,741 shares of the company’s stock valued at $2,583,000 after purchasing an additional 329,175 shares in the last quarter. Royal Bank of Canada raised its stake in shares of Karyopharm Therapeutics by 4.1% in the first quarter. Royal Bank of Canada now owns 60,399 shares of the company’s stock valued at $336,000 after purchasing an additional 2,399 shares in the last quarter. Commodore Capital LP acquired a new position in shares of Karyopharm Therapeutics in the first quarter valued at $10,862,000. OMERS ADMINISTRATION Corp acquired a new position in shares of Karyopharm Therapeutics in the first quarter valued at $108,000. Finally, Renaissance Technologies LLC raised its stake in shares of Karyopharm Therapeutics by 75.9% in the first quarter. Renaissance Technologies LLC now owns 105,414 shares of the company’s stock valued at $587,000 after purchasing an additional 45,500 shares in the last quarter. 66.44% of the stock is currently owned by institutional investors and hedge funds.

About Karyopharm Therapeutics

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.